C03BA08 metolazone

CARDIOVASCULAR SYSTEM DIURETICS LOW-CEILING DIURETICS, EXCL. THIAZIDES Sulfonamides, plain

健保收載品項 TFDA 在效許可證 6 FDA 已核准 健保給付條款 1

台灣藥品與外觀

台灣食藥署在效西藥許可證 6 張;以下列出 5 個品項(2 項有外觀照)。

健保收載品名:"應元" 美特平錠0.5公絲、"榮民"密克優錠 0.5 毫克、"瑪科隆"利舒壓 錠0.5毫克、立壓寧錠5公絲、脈可洛適錠 0.5 毫克、脈特舒錠 5 毫克、脈特舒錠2.5毫克、麥可適錠0.5公絲

無外觀照
"應元" 美特平錠0.5公絲
“榮民”密克優錠 0.5 毫克 外觀
“榮民”密克優錠 0.5 毫克
圓形 · 白 · 刻痕:無 · 標記:VPC / 143 · 6.3 mm
“瑪科隆”利舒壓 錠0.5毫克 外觀
“瑪科隆”利舒壓 錠0.5毫克
四邊形 · 白 · 刻痕:直線 · 標記:RP · 6 mm
無外觀照
脈可洛適錠 0.5 毫克
無外觀照
麥可適錠0.5毫克

資料來源:食藥署「西藥許可證」+「藥品 ATC 碼」+「藥品外觀」+「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。

適應症

台灣 TFDA 核准適應症

  1. 高血壓。

美國 FDA 適應症(英文原文對照)

美國 FDA 核准成分 metolazone (商品名 METOLAZONE / Metolazone) · 仿單更新 2025-03-19

INDICATIONS AND USAGE Metolazone is indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone is also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox ® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if Mykrox ® tablets are to be substituted for Zaroxolyn ® tablets and other formulations of metolazone that share its slow and incomplete bioavailability, in the treatment of hypertension. Usage In Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequence of pregnancy. Metolazone is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (see PRECAUTIONS ). Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may be appropriate.

資料來源:食藥署西藥許可證適應症(中文)、openFDA US SPL(英文,僅供對照)。

健保給付規定

上層 ATC 繼承條款

下列條款掛在較上層的 ATC 分類,依 ATC 階層也適用於本代碼。

繼承自 ATC C03

§ 2.9 利尿劑
心臟血管及腎臟藥物 › 利尿劑
利尿劑 (Diuretics)

實證補充

本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。


台灣藥品與適應症:食藥署西藥許可證+ATC+外觀+仿單開放資料 · FDA:openFDA US SPL · 健保給付:健保署「全民健康保險藥品給付規定」(更新日 2026-06-09)· 實證補充:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。